CaMKII Serine 280 O-GlcNAcylation Links Diabetic Hyperglycemia to Proarrhythmia

Supplemental Digital Content is available in the text. Rationale: Diabetic hyperglycemia is associated with cardiac dysfunction and increased arrhythmia risk, and CaMKII (calcium/calmodulin-dependent protein kinase II) function has been implicated. CaMKII activity is promoted by both oxidation and O-linked β-N-acetylglucosamine (O-GlcNAc) of known CaMKII sites. Objective: To investigate which posttranslational modifications occur in human diabetic hearts and how they alter electrophysiological and Ca2+ handling properties in hyperglycemia. Methods and Results: We assessed echocardiography, electrophysiology, Ca2+-handling, and protein expression in site-specific CaMKII mutant mice (O-GlcNAc-resistant S280A and oxidation-resistant MM281/2VV knock-ins, and global and cardiac-specific knockouts), in myocytes subjected to acute hyperglycemia and Ang II (angiotensin II) and mice after streptozotocin injections (to induce diabetes). Human patients with diabetes exhibit elevated CaMKII O-GlcNAcylation but not oxidation. In mice, acute hyperglycemia increased spontaneous diastolic Ca2+ sparks and waves and arrhythmogenic action potential changes (prolongation, alternans, and delayed afterdepolarizations), all of which required CaMKII-S280 O-GlcNAcylation. Ang II effects were dependent on NOX2 (NADPH oxidase 2)-mediated CaMKII MM281/2 oxidation. Diabetes led to much greater Ca2+ leak, RyR2 S2814 phosphorylation, electrophysiological remodeling, and increased susceptibility to in vivo arrhythmias, requiring CaMKII activation, predominantly via S280 O-GlcNAcylation and less via MM281/2 oxidation. These effects were present in myocytes at normal glucose but were exacerbated with the in vivo high circulating glucose. PLB (phospholamban) O-GlcNAcylation was increased and coincided with reduced PLB S16 phosphorylation in diabetes. Dantrolene, which reverses CaMKII-dependent proarrhythmic RyR-mediated Ca2+ leak, also prevented hyperglycemia-induced APD prolongation and delayed afterdepolarizations. Conclusions: We found that CaMKII-S280 O-GlcNAcylation is required for increased arrhythmia susceptibility in diabetic hyperglycemia, which can be worsened by an additional Ang II-NOX2-CaMKII MM281/2 oxidation pathway. CaMKII-dependent RyR2 S2814 phosphorylation markedly increases proarrhythmic Ca2+ leak and PLB O-GlcNAcylation may limit sarcoplasmic reticulum Ca2+ reuptake, leading to impaired excitation-contraction coupling and arrhythmogenesis in diabetic hyperglycemia.

[1]  Mark E. Anderson,et al.  Loss of CASK Accelerates Heart Failure Development , 2021, Circulation research.

[2]  D. Bers,et al.  Two-hit mechanism of cardiac arrhythmias in diabetic hyperglycemia: reduced repolarization reserve, neurohormonal stimulation and heart failure exacerbate susceptibility. , 2021, Cardiovascular research.

[3]  Manuel F. Navedo,et al.  Hyperglycemia regulates cardiac K+ channels via O-GlcNAc-CaMKII and NOX2-ROS-PKC pathways , 2020, Basic Research in Cardiology.

[4]  R. Cole,et al.  Oxidized-CaMKII and O-GlcNAcylation cause increased atrial fibrillation in diabetic mice by distinct mechanisms. , 2020, The Journal of clinical investigation.

[5]  D. Bers,et al.  Hyperglycemia Acutely Increases Cytosolic Reactive Oxygen Species via O-linked GlcNAcylation and CaMKII Activation in Mouse Ventricular Myocytes , 2020, Circulation research.

[6]  G. Filippatos,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2020, European heart journal.

[7]  F. Cosentino,et al.  The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.

[8]  A. Leite-Moreira,et al.  O-GlcNAcylation of Histone Deacetylase 4 Protects the Diabetic Heart from Failure. , 2019, Circulation.

[9]  W. Dillmann Diabetic Cardiomyopathy: What Is It and Can It Be Fixed? , 2019, Circulation research.

[10]  D. Bers,et al.  Enhanced Depolarization Drive in Failing Rabbit Ventricular Myocytes: Calcium-Dependent and &bgr;-Adrenergic Effects on Late Sodium, L-Type Calcium, and Sodium-Calcium Exchange Currents , 2019, Circulation. Arrhythmia and electrophysiology.

[11]  C. Yancy,et al.  Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[12]  D. Bers,et al.  Diabetic Hyperglycemia Regulates Potassium Channels and Arrhythmias in the Heart via Autonomous CaMKII Activation by O-Linked Glycosylation , 2019, Biophysical Journal.

[13]  D. Bers,et al.  CaMKII signaling in heart diseases: Emerging role in diabetic cardiomyopathy. , 2019, Journal of molecular and cellular cardiology.

[14]  D. Bers,et al.  Cardiac CaMKII activation promotes rapid translocation to its extra-dyadic targets. , 2018, Journal of molecular and cellular cardiology.

[15]  Ye Chen-Izu,et al.  β-adrenergic regulation of late Na+ current during cardiac action potential is mediated by both PKA and CaMKII. , 2018, Journal of molecular and cellular cardiology.

[16]  L. Maier,et al.  Empagliflozin reduces Ca/calmodulin‐dependent kinase II activity in isolated ventricular cardiomyocytes , 2018, ESC heart failure.

[17]  Zhong Jian,et al.  Complex electrophysiological remodeling in postinfarction ischemic heart failure , 2018, Proceedings of the National Academy of Sciences.

[18]  J. Sowers,et al.  Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity , 2018, Circulation research.

[19]  D. Bers,et al.  Altered Repolarization Reserve in Failing Rabbit Ventricular Myocytes: Calcium and &bgr;-Adrenergic Effects on Delayed- and Inward-Rectifier Potassium Currents , 2018, Circulation. Arrhythmia and electrophysiology.

[20]  E. Furlong,et al.  A proteolytic fragment of histone deacetylase 4 protects the heart from failure by regulating the hexosamine biosynthetic pathway , 2017, Nature Medicine.

[21]  Akshay S. Desai,et al.  Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. , 2017, The lancet. Diabetes & endocrinology.

[22]  F. Charpentier,et al.  The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model , 2017, Diabetes.

[23]  D. Bers,et al.  CaMKII-dependent phosphorylation of RyR2 promotes targetable pathological RyR2 conformational shift. , 2016, Journal of molecular and cellular cardiology.

[24]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[25]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[26]  R. Nishimura,et al.  Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study , 2015, Cardiovascular Diabetology.

[27]  A. Leite-Moreira,et al.  Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes , 2015, Cardiovascular Diabetology.

[28]  D. Vocadlo,et al.  The Emerging Link between O-GlcNAc and Alzheimer Disease* , 2014, The Journal of Biological Chemistry.

[29]  R. Ritchie,et al.  Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. , 2014, Pharmacology & therapeutics.

[30]  Junfeng Ma,et al.  O-GlcNAc profiling: from proteins to proteomes , 2014, Clinical Proteomics.

[31]  Mark E. Anderson,et al.  Mechanisms of Altered Ca2+ Handling in Heart Failure , 2013, Circulation research.

[32]  Gerald W. Hart,et al.  Diabetic Hyperglycemia activates CaMKII and Arrhythmias by O linked Glycosylation , 2013, Nature.

[33]  D. Bers,et al.  While systolic cardiomyocyte function is preserved, diastolic myocyte function and recovery from acidosis are impaired in CaMKIIδ-KO mice. , 2013, Journal of molecular and cellular cardiology.

[34]  I. Efimov,et al.  Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. , 2013, The Journal of clinical investigation.

[35]  W. Linke,et al.  Crucial Role for Ca2+/Calmodulin-Dependent Protein Kinase-II in Regulating Diastolic Stress of Normal and Failing Hearts via Titin Phosphorylation , 2013, Circulation research.

[36]  T. Saikawa,et al.  Activation of CaMKII as a key regulator of reactive oxygen species production in diabetic rat heart. , 2012, Journal of molecular and cellular cardiology.

[37]  Matthew S Macauley,et al.  Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. , 2012, Nature chemical biology.

[38]  D. Bers,et al.  Location Matters: Clarifying the Concept of Nuclear and Cytosolic CaMKII Subtypes , 2011, Circulation research.

[39]  Mark E. Anderson,et al.  Oxidation of CaMKII determines the cardiotoxic effects of aldosterone , 2011, Nature Medicine.

[40]  Donald M Bers,et al.  CaMKII in myocardial hypertrophy and heart failure. , 2011, Journal of molecular and cellular cardiology.

[41]  D. Bers,et al.  Fluorescence Resonance Energy Transfer–Based Sensor Camui Provides New Insight Into Mechanisms of Calcium/Calmodulin-Dependent Protein Kinase II Activation in Intact Cardiomyocytes , 2011, Circulation research.

[42]  F. Gueyffier,et al.  Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials , 2011, BMJ : British Medical Journal.

[43]  G. Hart,et al.  Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. , 2011, Annual review of biochemistry.

[44]  Ferdinando Giacco,et al.  Oxidative stress and diabetic complications. , 2010, Circulation research.

[45]  Keiichiro Suzuki,et al.  Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathy. , 2010, Glycobiology.

[46]  Steven P Jones,et al.  O-linked β-N-acetylglucosamine transferase is indispensable in the failing heart , 2010, Proceedings of the National Academy of Sciences.

[47]  C. Alpers,et al.  Mouse models of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.

[48]  Tong Zhang,et al.  Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. , 2009, The Journal of clinical investigation.

[49]  Hugo A. Katus,et al.  The δ isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload , 2009, Proceedings of the National Academy of Sciences.

[50]  Steven P Jones,et al.  Unique Hexosaminidase Reduces Metabolic Survival Signal and Sensitizes Cardiac Myocytes to Hypoxia/Reoxygenation Injury , 2008, Circulation research.

[51]  Mark E. Anderson,et al.  A Dynamic Pathway for Calcium-Independent Activation of CaMKII by Methionine Oxidation , 2008, Cell.

[52]  D. Bers Calcium cycling and signaling in cardiac myocytes. , 2008, Annual review of physiology.

[53]  Gerald W. Hart,et al.  Cycling of O-linked β-N-acetylglucosamine on nucleocytoplasmic proteins , 2007, Nature.

[54]  D. Bers,et al.  Ca2+/Calmodulin–Dependent Protein Kinase Modulates Cardiac Ryanodine Receptor Phosphorylation and Sarcoplasmic Reticulum Ca2+ Leak in Heart Failure , 2005, Circulation research.

[55]  T. Rea,et al.  Diabetes, glucose level, and risk of sudden cardiac death. , 2005, European heart journal.

[56]  G. Lip,et al.  Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart. , 2004, Archives of internal medicine.

[57]  Andy Hudmon,et al.  Structure-function of the multifunctional Ca2+/calmodulin-dependent protein kinase II. , 2002, The Biochemical journal.

[58]  D. Bers Cardiac excitation–contraction coupling , 2002, Nature.

[59]  G. Tomaselli,et al.  Electrophysiological remodeling in hypertrophy and heart failure. , 1999, Cardiovascular research.

[60]  C. Carlson,et al.  Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure. , 2012, Physiological genomics.

[61]  A. Ceriello Postprandial hyperglycemia and diabetes complications: is it time to treat? , 2005, Diabetes.

[62]  Kumar Sharma,et al.  Mouse models of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.